The $180M sale is a significant positive catalyst for RCKTW given the tiny market cap (~$1M). Monitor HSR clearance and closing. If completed, expect a sharp re-rating as cash balances will vastly exceed current market cap.
Price Chart
Executive Summary
Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, providing non-dilutive capital that extends the company's cash runway into the second quarter of 2028. This strengthens the balance sheet and supports advancement of its cardiovascular gene therapy pipeline.
Key Financial Metrics
Key Facts
- Sold Rare Pediatric Disease Priority Review Voucher for $180 million in cash
- Proceeds are non-dilutive and expected to extend cash runway into Q2 2028
- Transaction subject to HSR waiting period expiration or termination
- PRV was awarded from FDA accelerated approval of KRESLADI (marnetegragene autotemcel)
Financial Impact
$180 million cash inflow, extending cash runway into Q2 2028
Risk Factors
- Transaction may not close due to HSR or other conditions
- Proceeds do not guarantee success of pipeline programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-017275 |
| Document: ef20071574_ex99-1.htm | 0001140361-26-017275 |
| Document: 0001140361-26-017275-index-headers.html | 0001140361-26-017275 |
| Document: 0001140361-26-017275-index.html | 0001140361-26-017275 |
| Document: 0001140361-26-017275.txt | 0001140361-26-017275 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 13, 2026 20w ago | 144 | $0.0193 $0.0193 | · 0.00% | ▲ +0.61% | — |
May 7, 2026 21w ago | 8-K | $0.0193 $0.0193 | · 0.00% | ▼ −0.02% | — |
May 7, 2026 21w ago | 144 | $0.0193 $0.0193 | · 0.00% | ▼ −3.14% | — |
Apr 28, 2026 22w ago | 8-K | $0.0193 $0.0193 | · 0.00% | ▼ −5.46% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access